Get the Flash Player to see this video.

MacroGenics’ mission is to discover, develop and deliver to patients novel biologics for the treatment of cancer, autoimmune disorders and infectious diseases.  Learn More

  MacroGenics' Corporate Fact Sheet

Product Pipeline Highlights

View full chart
Program (Target) Indication Pre-
Clin.
Ph.
1
Ph.
2
Ph.
3
ONCOLOGY        
Margetuximab  (HER2) Gastroesophageal *  *  *  * 
Metastatic Breast *  *  *  * 
Solid Tumors *  *  *  * 
MGA271  (B7-H3) Solid Tumors *  *  *  * 
MGD006  (CD123 x CD3) AML *  *  *  * 
MGD007  (gpA33 x CD3) Gastrointestinal *  *  *  * 
AUTOIMMUNE        
Teplizumab  (CD3) T1D - At-Risk *  *  *  * 
MGD010  (CD32B x CD79B) Lupus, RA *  *  *  * 

Overview

Since its founding in 2000, MacroGenics has applied its world-class antibody capabilities to create life-changing medicines. The company’s innovative product candidates leverage its fully-integrated capabilities and its multiple, proprietary technology platforms.

Learn more

Company Highlights

  • Robust pipeline in oncology and autoimmune disorders
  • Partners include Takeda, Gilead, Servier, Pfizer and Boehringer Ingelheim
  • Fully-integrated biologics capabilities across product development process 
  • Strong financial position
  • Experienced leadership and highly collaborative corporate culture 
Learn more

DART Platform

"10 Next-gen Biologics
Platforms to Watch”
Learn more

Partnering


Jan. '13 - Strategic alliance with Gilead on four DARTs.
Sep. '12 - Collaboration with Servier on multiple oncology DARTs.
Dec.  '11 - Collaboration with Servier on MGA271.
Oct. '10 - Global DART partnerships with Pfizer and Boehringer Ingelheim. Learn more